The Principal Scientist will lead the research and early development of programs targeting genetic heart disease/genetic cardiomyopathies, including formation of cross-functional program teams and, in partnership with the CV team, building short- and long-range plans and establishing key go/no-go decision-making criteria. In addition to leading an early program team, the Principal Scientist will be a key scientific leader in the group, interfacing with program teams developing other novel therapeutics for inherited heart diseases and will play a leadership role in helping to set the strategic direction for the company's interest in genetic cardiac diseases, including the assessment of new target/therapeutic concepts and the evaluation of potential business development opportunities. The Principal Scientist will also manage several direct reports.
The successful candidate will have a strong background in cardiovascular physiology and pharmacology, with demonstrated experience in the application of novel therapeutic paradigms for genetic heart diseases. Experience in cardiovascular genetics, functional cardiomyocyte assays and familiarity with other core techniques, such as cardiac electrophysiology and echocardiography would also be beneficial.
The successful candidate will have experience providing context of findings to senior management and offering insights to inform continued clinical development of programs for genetic cardyomyopathies. The candidate will communicate, publish, and present scientific data and conclusions, along with their potential translatability to humans, to project teams, external collaborators, and the scientific community.
Develop novel programs based on innovative, ground-breaking discoveries that could lead to new, high-impact therapeutic opportunities for patients.
Lead a cross-functional preclinical research team in the development of novel therapeutics for genetic cardiomyopathies
Direct research and publish findings in high-impact journals and present research at major conferences.
Effectively partner with the program team, other scientists and the Research and Early Development leadership team to develop and execute on the programs' strategic plans.
Present program data at a range of internal forums, including Research Seminars and Leadership Team governance forums.
Provide senior scientific leadership and guide the strategic direction of the company's efforts in the Genetic Cardiomyopathy therapeutic area, including developing and evaluating new internal and external therapeutic opportunities.
Manage, mentor and guide a focused team of in vitro / in vivo cardiovascular scientists.
Review and contribute to study synopses, protocols, study reports and regulatory documents.
Collaborate with various company functions, CROs, university or analytical laboratories, business partners, as necessary to ensure appropriate/timely progression of projects.
Participate in multi-disciplinary drug development teams and may lead sub-teams.
Excellent written and verbal communication skills.
Ability to build/foster productive cross-functional collaborations both within and external to the company.
Required: Ph.D. with strong experience in cardiovascular research and cardiovascular physiology, pharmacology or a related subject area.
Education & Experience Level:
PhD or equivalent relevant experience plus 10+ years industry experience
PLEASE NOTE: Absent a Medical or Religious reason that prohibits vaccinations, all our incoming employees must be vaccinated for COVID-19.
We are an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity, sexual orientation, national origin, disability status, protected veteran status, or any other characteristic protected by law.